Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Novembro 2023 - 5:32PM
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq:
OLMA), a clinical-stage biopharmaceutical company focused on the
discovery, development, and commercialization of targeted therapies
for women’s cancers, today announced that the Company granted stock
options to two new employees to purchase an aggregate of 85,000
shares of the Company's common stock, effective as of November 1,
2023. These awards were approved by the Compensation Committee of
Olema’s Board of Directors and granted under the Company's 2022
Inducement Plan, with a grant date of November 1, 2023, as an
inducement material to the new employee entering into employment
with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting
on the first anniversary of the vesting commencement date for such
employee and the remainder vesting in 36 equal monthly installments
over the following three years, subject to the employee being
continuously employed by Olema as of such vesting dates. The stock
options have a 10-year term and an exercise price of $14.94 per
share, equal to the last reported sale price of the Company's
common stock as reported by Nasdaq on November 1, 2023. The stock
options are subject to the terms of the Olema Pharmaceuticals,
Inc., 2022 Inducement Plan.
Olema is providing this information in accordance with Nasdaq
Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
targeted therapies for women’s cancers. Olema’s lead product
candidate, palazestrant (OP-1250), is a proprietary,
orally-available small molecule with dual activity as both a
complete estrogen receptor (ER) antagonist (CERAN) and a selective
ER degrader (SERD). It is currently being evaluated both as a
single agent in an ongoing Phase 2 clinical trial, and in
combination with CDK4/6 inhibitors (palbociclib and ribociclib) and
a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally
advanced or metastatic ER-positive (ER+), human epidermal growth
factor receptor 2-negative (HER2-) breast cancer. Palazestrant has
been granted FDA Fast Track designation for the treatment of
ER+/HER2- metastatic breast cancer that has progressed following
one or more lines of endocrine therapy with at least one line given
in combination with a CDK4/6 inhibitor. Olema is headquartered in
San Francisco and has operations in Cambridge, Massachusetts. For
more information, please visit us at www.olema.com, or follow us on
Twitter and LinkedIn.
Contact:Geoffrey Mogilner, Vice President, Investor Relations
and Communicationsir@olema.com
Olema Pharmaceuticals (NASDAQ:OLMA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Olema Pharmaceuticals (NASDAQ:OLMA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024